Published in final edited form as:

J Perinat Med. 2016 January ; 44(1): 23–32. doi:10.1515/jpm-2015-0044.

Clinical chorioamnionitis at term III: how well do clinical criteria perform in the identification of proven intra-amniotic infection?

Roberto Romero, MD, D.Med.Sci.^{1,2,3,4}, Piya Chaemsathong, MD^{1,5}, Steven J. Korzeniewski, PhD^{1,3,5}, Juan P. Kusanovic, MD^{1,6,7}, Nikolina Docheva, BMBS^{1,5}, Alicia Martinez-Varea, MD^{1,5}, Ahmed I. Ahmed, MD^{1,5}, Bo Hyun Yoon, MD, PhD⁸, Sonia S. Hassan, MD^{1,5}, Tinnakorn Chaiworapongsa, MD^{1,5}, and Lami Yeo, MD^{1,5}

¹Perinatology Research Branch, Program for Perinatal Research and Obstetrics, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD and Detroit, MI, USA

²Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA

³Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, USA

⁴Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, USA

⁵Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, USA

⁶Center for Research and Innovation in Maternal-Fetal Medicine (CIMAF), Sótero del Río Hospital, Santiago, Chile

⁷Division of Obstetrics and Gynecology, Pontificia Universidad Católica de Chile, Santiago, Chile

⁸Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea

Abstract

Objective—The diagnosis of clinical chorioamnionitis is based on a combination of signs [fever, maternal or fetal tachycardia, foul-smelling amniotic fluid (AF), uterine tenderness, and maternal leukocytosis]. Bacterial infections within the amniotic cavity are considered the most frequent cause of clinical chorioamnionitis and an indication for antibiotic administration to reduce maternal and neonatal morbidity. Recent studies show that only 54% of patients with the diagnosis of clinical chorioamnionitis at term have bacteria in the AF and evidence of intra-amniotic inflammation. The objective of this study was to examine the performance of the clinical criteria for the diagnosis of chorioamnionitis to identify patients with microbial-associated intra-amniotic inflammation (also termed intra-amniotic infection).

Materials and methods—This retrospective cross-sectional study included 45 patients with the diagnosis of clinical chorioamnionitis at term, whose AF underwent analysis for: 1) the presence of microorganisms using both cultivation and molecular biologic techniques [polymerase chain

reaction (PCR) with broad primers] and 2) interleukin (IL)-6 concentrations by enzyme-linked immunosorbent assay. The diagnostic performance (sensitivity, specificity, accuracy, and likelihood ratios) of each clinical sign and their combination to identify clinical chorioamnionitis were determined using microbial-associated intra-amniotic inflammation [presence of microorganisms in the AF using cultivation or molecular techniques and elevated AF IL-6 concentrations (> 2.6 ng/mL)] as the gold standard.

Results—The accuracy of each clinical sign for the identification of microbial-associated intra-amniotic inflammation (intra-amniotic infection) ranged between 46.7% and 57.8%. The combination of fever with three or more clinical criteria did not substantially improve diagnostic accuracy.

Conclusion—In the presence of a fever during labor at term, signs used to diagnose clinical chorioamnionitis do not accurately identify the patient with proven intra-amniotic infection (i.e., those with microorganisms detected by culture or molecular microbiologic techniques and an associated intra-amniotic inflammatory response).

Keywords

amniocentesis; fever; foul-smelling amniotic fluid; funisitis; histological chorioamnionitis; intra-amniotic inflammation; maternal leukocytosis; preterm birth; sterile inflammation; tachycardia; uterine tenderness

Introduction

The term “clinical chorioamnionitis” refers to an entity diagnosed by the presence of fever ($\geq 37.8^{\circ}\text{C}$) and at least two of the following criteria: maternal tachycardia (> 100 beats per minute), maternal leukocytosis [white blood cell count (WBC) $> 15,000$ cells/mm³], uterine tenderness, fetal tachycardia (> 160 beats per minute), and foul-smelling amniotic fluid (AF) (1–10). More than 35 years ago, Gibbs recognized the challenges in the diagnosis of intra-amniotic infection (microbial-associated intra-amniotic inflammation), as he indicated that the clinical criteria were neither sensitive nor specific (1).

The clinical diagnosis of chorioamnionitis is an indication for antimicrobial administration, given that a randomized clinical trial of patients with this condition near term found that the frequency of neonatal bacteremia was significantly greater in patients who were not given antibiotics before delivery than in those who were treated in the neonatal period. This classic trial by Gibbs *et al* is the basis for clinical practice today (6).

Epidural anesthesia and analgesia for labor and delivery have gained wide acceptance and are used in more than 80% of cases in maternity hospitals (11, 12). About 10% to 30% of patients who receive epidural analgesia develop a fever (11–29), and the differential diagnosis between clinical chorioamnionitis and an epidural-induced fever is challenging. This has resulted in the increased administration of antibiotics to mothers in labor (17, 18, 21, 30, 31) and their newborns (18, 21, 32, 33) and in the implementation of septic work-ups in newborns (11, 12, 15, 18, 21, 25, 32, 34, 35). Recent evidence suggests that the administration of antibiotics has important effects on the microbiome in adults (36–46) and in the neonatal period (37, 40, 43–45, 47–68).

We recently reported, when the AF of patients with clinical chorioamnionitis at term is examined using cultivation and molecular microbiologic techniques, that only 54% of patients have microbial-associated intra-amniotic inflammation in the amniotic cavity (69). Moreover, 24% of patients have intra-amniotic inflammation without detectable bacteria, and 22% do not have any evidence of intra-amniotic inflammation (69). Traditionally, one expects that only patients with bacterial infections may benefit from antibiotic administration; however, our observations suggest that relying on the conventional criteria for the diagnosis of clinical chorioamnionitis may result in over-treatment with antimicrobial agents. Therefore, it is timely that the diagnostic performance and accuracy of clinical signs for the diagnosis of clinical chorioamnionitis be revisited using a gold standard for the identification of microbial-associated intra-amniotic inflammation, which represents intra-amniotic infection.

Materials and methods

This retrospective cross-sectional study included women with the diagnosis of clinical chorioamnionitis at term who underwent amniocentesis to identify microorganisms in the amniotic cavity. Patients were identified by searching the clinical database and Bank of Biologic Samples of Wayne State University, the Detroit Medical Center and the Perinatology Research Branch (NICHD/NIH/DHHS). The criteria for entry were: 1) singleton gestation; 2) gestational age ≥ 37 weeks; 3) sufficient AF obtained by transabdominal amniocentesis for molecular microbiologic studies; and 4) absence of fetal malformations. A subset of these patients was included in prior studies that provide a detailed description of the sample collection, microbiological studies, and determination of AF IL-6 concentrations (69, 70).

All patients provided written informed consent, and the use of biological specimens as well as clinical and ultrasound data for research purposes were approved by the Institutional Review Boards of NICHD, Wayne State University, and the Sótero del Río Hospital, Santiago, Chile.

Clinical definitions

Microbial invasion of the amniotic cavity (MIAC) was defined according to the results of AF culture and PCR/ESI-MS (Ibis® Technology, Athogen, Carlsbad, CA) (71–74). Microbial-associated intra-amniotic inflammation (intra-amniotic infection) was diagnosed when microorganisms were identified in the AF using cultivation or molecular techniques and elevated AF IL-6 concentrations (≥ 2.6 ng/mL) were found, as described in detail elsewhere (69, 75–92).

Clinical chorioamnionitis was diagnosed by the presence of maternal fever (temperature $>37.8^{\circ}\text{C}$) accompanied by two or more of the following criteria: 1) maternal tachycardia (heart rate >100 beats/min); 2) uterine tenderness; 3) foul-smelling AF; 4) fetal tachycardia (heart rate >160 beats/min); and 5) maternal leukocytosis (leukocyte count $>15,000$ cells/mm³) (1–9, 69, 70, 80). Acute histologic chorioamnionitis was diagnosed based on the presence of inflammatory cells in the chorionic plate and/or in the chorioamniotic membranes (77, 83, 93–102), and acute funisitis was diagnosed by the presence of

neutrophils in the wall of the umbilical vessels and/or in the Wharton's jelly, also using previously reported criteria (93, 103–108). Fetal inflammatory response syndrome (FIRS) was diagnosed when umbilical cord blood IL-6 concentrations were ≥ 11 pg/mL. (72, 105, 109–119).

Statistical analysis

The Kolmogorov-Smirnov test was used to test whether data were normally distributed. A Chi-square or Fisher's exact test was used for comparisons of proportions. Kruskal-Wallis and the Mann-Whitney *U*-tests were used to compare median concentrations of analytes between and among the groups. Sensitivity, specificity, accuracy, and likelihood ratios (+/-) were calculated for the identification of microbial-associated intra-amniotic inflammation. Statistical analysis was performed using SPSS 19 (IBM Corp, Armonk, NY, USA). A *p* value < 0.05 was considered statistically significant.

Results

Descriptive Characteristics

The descriptive characteristics of the study population stratified by the presence or absence of microbial-associated intra-amniotic inflammation or intra-amniotic infection are displayed in Table 1. Fever was a requirement for the diagnosis of clinical chorioamnionitis. The most frequent clinical signs of chorioamnionitis were maternal tachycardia (91.1%; 41/45), followed by fetal tachycardia (75.6%; 34/45), and maternal leukocytosis (WBCs $> 15,000$ cells/mm³) (73.3%; 33/45). Uterine tenderness and foul-smelling AF were found in less than 10% of the study population (uterine tenderness: 8.9%, 4/45; foul-smelling AF: 6.7%, 3/45) (Table 1). There were no significant differences in the frequency of each clinical sign between clinical chorioamnionitis with and without microbial-associated intra-amniotic inflammation (*p* > 0.05). All patients had an epidural. Amniocenteses were performed before the administration of epidural analgesia in 78% (35/45) of the study participants. All but two of these women received antibiotics, which were administered in most of the cases (88.4%; 38/43) after amniocentesis (Table 1). In three patients, the amniocentesis was performed approximately five minutes after the administration of antibiotics, and, in two women, the amniocentesis was performed 45 minutes after treatment. The information about the microorganisms identified in the AF has been published previously (69). The most frequent microorganisms were *Ureaplasma* spp. and *Gardnerella vaginalis* (69).

Patients with clinical chorioamnionitis at term with microbial-associated intra-amniotic inflammation had a significantly higher median AF WBC count, AF IL-6, and umbilical cord blood IL-6 concentration than those without microbial-associated intra-amniotic inflammation (*p* <0.001 , *p* <0.001 , and *p* $=0.03$, respectively). The frequencies of FIRS and acute inflammatory lesions of the placenta were also significantly greater in patients with clinical chorioamnionitis at term with microbial-associated intra-amniotic inflammation than in those without microbial-associated intra-amniotic inflammation (FIRS: 36% vs. 5%; *p* $=0.03$; and acute inflammatory lesions of the placenta: 70.8% vs. 25%; *p* $=0.02$) (Table 1).

Diagnostic performance

The performance of criteria for the diagnosis of clinical chorioamnionitis in the identification of microbial-associated intra-amniotic inflammation is shown in Table 2. The sensitivity of maternal and fetal tachycardia and maternal leukocytosis ranged from 75% to 90%; however, the specificity was poor for these criteria, ranging from 0% to 30%. In contrast, foul-smelling AF and uterine tenderness had a high specificity (95%) but a low sensitivity (8% and 12%, respectively) for the identification of microbial-associated intra-amniotic inflammation. Altogether, the diagnostic accuracy for each clinical criterion ranged between 46.7% and 57.8%. The combination of fever with three or more clinical criteria did not further improve the diagnostic accuracy for the identification of microbial-associated intra-amniotic inflammation (Table 2).

Table 3 shows the diagnostic indices for the identification of intra-amniotic inflammation, regardless of the presence or absence of microorganisms detected by cultivation or molecular microbiologic techniques.

Discussion

Criteria for the diagnosis of clinical chorioamnionitis have considerable limitations if the goal is to identify the patient with bacterial-associated intra-amniotic inflammation. The standard diagnostic criteria of clinical chorioamnionitis include fever and two or more of the following: maternal and fetal tachycardia, uterine tenderness, foul-smelling AF, and maternal leukocytosis (1–10). The rationale for the precise cut-off used to define fever and maternal and fetal tachycardia was discussed in detail by Newton (8), who articulated that the thresholds for maternal and fetal tachycardia are the 90th percentile (8), and for the WBC count, the 80th percentile (120).

Our findings indicate that clinical signs of chorioamnionitis do not accurately identify patients with microbial-associated intra-amniotic inflammation or intra-amniotic infection. Maternal and fetal tachycardia as well as maternal leukocytosis had low specificity (5% to 30%), whereas foul-smelling AF and uterine tenderness had poor sensitivity (<15%) for the diagnosis of microbial-associated intra-amniotic inflammation. Our observations are consistent with those of a prior study that demonstrated that fever and maternal and fetal tachycardia were not reliable for the identification of acute histologic chorioamnionitis (121). Several investigators have shown that the majority of women with acute inflammatory placental lesions do not have microorganisms detectable using either cultivation or molecular microbiologic techniques in the chorioamniotic membranes (122–129). Histologic chorioamnionitis is more sensitive than clinical chorioamnionitis in the identification of patients with AF cultures positive for microorganisms (130).

The diagnosis of intra-amniotic infection in this study was based on the combination of the presence of microorganisms identified by cultivation or molecular microbiologic methods and intra-amniotic inflammation as a gold standard (71–74, 83–86, 88, 89, 131). We previously reported that intra-amniotic inflammation with detectable microorganisms was associated with acute histologic chorioamnionitis and funisitis (69, 83–86) and elevated inflammation-related protein concentrations in the AF (70, 83–86).

Efforts to improve the identification of patients with proven intra-amniotic infection are worthwhile because a high rate of false-positive diagnoses has clinical and financial implications. Often, mothers with a fever during labor are given antibiotics (17, 18, 21, 30, 31) – such intervention renders the results of neonatal cultures less reliable, and this frequently results in antibiotic administration during the neonatal period (18, 21, 32, 33), increased septic work-ups (11, 12, 15, 18, 21, 25, 32, 34, 35), and separation of the neonates from the parents while antibiotic treatment takes place in the nursery (132–135).

We propose that the analysis of the AF obtained using a transcervical AF collector may facilitate the rapid diagnosis of patients with intra-amniotic inflammation from those who do not have an inflammatory process (136). Further studies are required to determine if such an approach may reduce the utilization of antibiotics in both patients in labor and in the neonatal period.

The major strength of this study is that both cultivation and molecular microbiologic techniques were used to identify microorganisms in the amniotic cavity collected by transabdominal amniocentesis – therefore, the diagnosis of microbial invasion is based on a gold standard. Most work in clinical chorioamnionitis has been based on a case definition that relies heavily on clinical signs. The shortcomings of such an approach have become clear, now that sterile inflammation has emerged as an important entity for patients at term (137) as well as for those in preterm labor (83, 86), those with preterm prelabor rupture of the membranes (84), or those with an asymptomatic sonographic short cervix (85). Non-microbial-associated inflammation appears to account for a sizable segment of patients with clinical chorioamnionitis at term (69, 80).

Conclusion

Criteria used for the diagnosis of clinical chorioamnionitis at term do not accurately identify the subset of patients with intra-amniotic infection or bacterial-associated intra-amniotic inflammation. Further work is required to explore whether such diagnosis is possible by using AF obtained with a transcervical AF collector (136).

References

1. Gibbs RS. Diagnosis of intra-amniotic infection. *Semin Perinatol.* 1977; 1:71–7. [PubMed: 106471]
2. MacVicar J. Chorioamnionitis. *Clin Obstet Gynecol.* 1970; 13:272–90. [PubMed: 4923485]
3. Gibbs RS, Castillo MS, Rodgers PJ. Management of acute chorioamnionitis. *Am J Obstet and Gynecol.* 1980; 136:709–13. [PubMed: 7355955]
4. Gibbs RS, Blanco JD, St Clair PJ, Castaneda YS. Quantitative bacteriology of amniotic fluid from women with clinical intraamniotic infection at term. *Journal Infect Dis.* 1982; 145:1–8. [PubMed: 7033397]
5. Hollander D. Diagnosis of chorioamnionitis. *Clin Obstet Gynecol.* 1986; 29:816–25. [PubMed: 3545586]
6. Gibbs RS, Dinsmoor MJ, Newton ER, Ramamurthy RS. A randomized trial of intrapartum vs. immediate postpartum treatment of women with intra-amniotic infection. *Obstet Gynecol.* 1988; 72:823–8. [PubMed: 3186087]
7. Gilstrap LC 3rd, Cox SM. Acute chorioamnionitis. *Obstet Gynecol Clin of N Am.* 1989; 16:373–9.
8. Newton ER. Chorioamnionitis and intraamniotic infection. *Clin Obstet Gynecol.* 1993; 36:795–808. [PubMed: 8293582]

9. Tita AT, Andrews WW. Diagnosis and management of clinical chorioamnionitis. *Clin Perinatol*. 2010; 37:339–54. [PubMed: 20569811]
10. Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. *Science*. 2014; 345:760–5. [PubMed: 25124429]
11. Yancey MK, Zhang J, Schwarz J, Dietrich CS 3rd, Klebanoff M. Labor epidural analgesia and intrapartum maternal hyperthermia. *Obstet Gynecol*. 2001; 98:763–70. [PubMed: 11704166]
12. Kaul B, Vallejo M, Ramanathan S, Mandell G. Epidural labor analgesia and neonatal sepsis evaluation rate: a quality improvement study. *Anesth Analg*. 2001; 93:986–90. [PubMed: 11574370]
13. Gleeson NC, Nolan KM, Ford MR. Temperature, labour, and epidural analgesia. *Lancet*. 1989; 2:861–2.
14. Fusi L, Steer PJ, Maresh MJ, Beard RW. Maternal pyrexia associated with the use of epidural analgesia in labour. *Lancet*. 1989; i:1250–2.
15. Vinson DC, Thomas R, Kiser T. Association between epidural analgesia during labor and fever. *J Fam Pract*. 1993; 36:617–22. [PubMed: 8505604]
16. Ramin SM, Gambling DR, Lucas MJ, Sharma SK, Sidawi JE, Leveno KJ. Randomized trial of epidural vs. intravenous analgesia during labor. *Obstet Gynecol*. 1995; 86:783–9. [PubMed: 7566849]
17. Mayer DC, Chescheir NC, Spielman FJ. Increased intrapartum antibiotic administration associated with epidural analgesia in labor. *Am J Perinatol*. 1997; 14:83–6. [PubMed: 9259904]
18. Lieberman E, Lang JM, Frigoletto F Jr, Richardson DK, Ringer SA, Cohen A. Epidural analgesia, intrapartum fever, and neonatal sepsis evaluation. *Pediatrics*. 1997; 99:415–9. [PubMed: 9041298]
19. Sharma SK, Sidawi JE, Ramin SM, Lucas MJ, Leveno KJ, Cunningham FG. Cesarean delivery: a randomized trial of epidural vs. patient-controlled meperidine analgesia during labor. *Anesthesiology*. 1997; 87:487–94. [PubMed: 9316951]
20. Dashe JS, Rogers BB, McIntire DD, Leveno KJ. Epidural analgesia and intrapartum fever: placental findings. *Obstet Gynecol*. 1999; 93:341–4. [PubMed: 10074975]
21. Philip J, Alexander JM, Sharma SK, Leveno KJ, McIntire DD, Wiley J. Epidural analgesia during labor and maternal fever. *Anesthesiology*. 1999; 90:1271–5. [PubMed: 10319772]
22. Lucas MJ, Sharma SK, McIntire DD, Wiley J, Sidawi JE, Ramin SM, et al. A randomized trial of labor analgesia in women with pregnancy-induced hypertension. *Am J Obstet Gynecol*. 2001; 185:970–5. [PubMed: 11641687]
23. Sharma SK, Alexander JM, Messick G, Bloom SL, McIntire DD, Wiley J, et al. Cesarean delivery: a randomized trial of epidural analgesia vs. intravenous meperidine analgesia during labor in nulliparous women. *Anesthesiology*. 2002; 96:546–51. [PubMed: 11873026]
24. Goetzl L, Rivers J, Zighelboim I, Wali A, Badell M, Suresh MS. Intrapartum epidural analgesia and maternal temperature regulation. *Obstet Gynecol*. 2007; 109:687–90. [PubMed: 17329521]
25. Segal S. Labor epidural analgesia and maternal fever. *Anesth Analg*. 2010; 111:1467–75. [PubMed: 20861420]
26. Agakidis C, Agakidou E, Philip Thomas S, Murthy P, John Lloyd D. Labor epidural analgesia is independent risk factor for neonatal pyrexia. *J Matern Fetal Neonatal Med*. 2011; 24:1128–32. [PubMed: 21247230]
27. Goetzl L. Epidural analgesia and maternal fever: a clinical and research update. *Curr Opin Anaesthesiol*. 2012; 25:292–9. [PubMed: 22473213]
28. Greenwell EA, Wyshak G, Ringer SA, Johnson LC, Rivkin MJ, Lieberman E. Intrapartum temperature elevation, epidural use, and adverse outcome in term infants. *Pediatrics*. 2012; 129:e447–54. [PubMed: 22291120]
29. Arendt KW, Segal BS. The association between epidural labor analgesia and maternal fever. *Clin Perinatol*. 2013; 40:385–98. [PubMed: 23972746]
30. Goetzl L, Cohen A, Frigoletto F Jr, Lang JM, Lieberman E. Maternal epidural analgesia and rates of maternal antibiotic treatment in a low-risk nulliparous population. *J Perinatol*. 2003; 23:457–61. [PubMed: 13679931]

31. Apantaku O, Mulik V. Maternal intra-partum fever. *J Obstet Gynaecol.* 2007; 27:12–15. [PubMed: 17365450]
32. Herbst A, Wolner-Hanssen P, Ingemarsson I. Risk factors for fever in labor. *Obstet Gynecol.* 1995; 86:790–4. [PubMed: 7566850]
33. Goetzl L. Epidural fever in obstetric patients: it's a hot topic. *Anesth Analg.* 2014; 118:494–5. [PubMed: 24557092]
34. Pleasure JR, Stahl GE. Epidural analgesia and neonatal fever. *Pediatrics.* 1998; 101:490. author reply 3–4.
35. Goetzl L, Cohen A, Frigoletto F Jr, Ringer SA, Lang JM, Lieberman E. Maternal epidural use and neonatal sepsis evaluation in afebrile mothers. *Pediatrics.* 2001; 108:1099–1102. [PubMed: 11694687]
36. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. *Lancet Infect Dis.* 2001; 1:101–14. [PubMed: 11871461]
37. Noverr MC, Huffnagle GB. The “microflora hypothesis” of allergic diseases. *ClinExp Allergy.* 2005; 35:1511–20.
38. Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. *PloS One.* 2010; 5:e9836. [PubMed: 20352091]
39. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. *Microbiology.* 2010; 156:3216–3223. [PubMed: 20705661]
40. Young VB. The intestinal microbiota in health and disease. *Curr Opin Gastroenterol.* 2012; 28:63–9. [PubMed: 22080827]
41. Mangin I, Leveque C, Magne F, Suau A, Pochart P. Long-term changes in human colonic *Bifidobacterium* populations induced by a 5-day oral amoxicillin-clavulanic acid treatment. *PloS One.* 2012; 7:e50257. [PubMed: 23209691]
42. Marild K, Ye W, Lebwohl B, Green PH, Blaser MJ, Card T, et al. Antibiotic exposure and the development of coeliac disease: a nationwide case-control study. *BMC Gastroenterol.* 2013; 13:109. [PubMed: 23834758]
43. Jess T. Microbiota, antibiotics, and obesity. *N Engl J Med.* 2014; 371:2526–8. [PubMed: 25539109]
44. Cox LM, Blaser MJ. Antibiotics in early life and obesity. *Nat Rev Endocrinol.* 2015; 11:182–90. [PubMed: 25488483]
45. Cox LM, Yamanishi S, Sohn J, Alekseyenko AV, Leung JM, Cho I, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. *Cell.* 2014; 158:705–21. [PubMed: 25126780]
46. Panda S, El Khader I, Casellas F, Lopez Vivancos J, Garcia Cors M, Santiago A, et al. Short-term effect of antibiotics on human gut microbiota. *PloS One.* 2014; 9:e95476. [PubMed: 24748167]
47. Fanaro S, Chierici R, Guerrini P, Vigi V. Intestinal microflora in early infancy: composition and development. *Acta Paediatr.* 2003; 91:48–55.
48. Schumann A, Nutten S, Donnicola D, Comelli EM, Mansourian R, Cherbut C, et al. Neonatal antibiotic treatment alters gastrointestinal tract developmental gene expression and intestinal barrier transcriptome. *Physiol Genomics.* 2005; 23:235–45. [PubMed: 16131529]
49. Wall R, Ross RP, Ryan CA, Hussey S, Murphy B, Fitzgerald GF, et al. Role of gut microbiota in early infant development. *Clin Med Pediatr.* 2009; 3:45–54. [PubMed: 23818794]
50. Tanaka S, Kobayashi T, Songjinda P, Tateyama A, Tsubouchi M, Kiyohara C, et al. Influence of antibiotic exposure in the early postnatal period on the development of intestinal microbiota. *FEMS Immunol Med Microbiol.* 2009; 56:80–7. [PubMed: 19385995]
51. Marques TM, Wall R, Ross RP, Fitzgerald GF, Ryan CA, Stanton C. Programming infant gut microbiota: influence of dietary and environmental factors. *Curr Opin Biotechnol.* 2010; 21:149–56. [PubMed: 20434324]
52. Mangin I, Suau A, Gotteland M, Brunser O, Pochart P. Amoxicillin treatment modifies the composition of *Bifidobacterium* species in infant intestinal microbiota. *Anaerobe.* 2010; 16:433–8. [PubMed: 20601031]

53. Hviid A, Svanstrom H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. *Gut*. 2011; 60:49–54. [PubMed: 20966024]
54. Ajslev TA, Andersen CS, Gamborg M, Sorensen TI, Jess T. Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. *Int J Obes*. 2011; 35:522–9.
55. Madan JC, Salari RC, Saxena D, Davidson L, O'Toole GA, Moore JH, et al. Gut microbial colonisation in premature neonates predicts neonatal sepsis. *Arch Dis Child Fetal Neonatal Ed*. 2012; 97:F456–62. [PubMed: 22562869]
56. Russell SL, Gold MJ, Hartmann M, Willing BP, Thorson L, Wlodarska M, et al. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. *EMBO Rep*. 2012; 13:440–7. [PubMed: 22422004]
57. Fouhy F, Guinane CM, Hussey S, Wall R, Ryan CA, Dempsey EM, et al. High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. *Antimicrob Agents Chemotherapy*. 2012; 56:5811–20.
58. Romero R, Korzeniewski SJ. Are infants born by elective cesarean delivery without labor at risk for developing immune disorders later in life? *Am J Obstet Gynecol*. 2013; 208:243–6. [PubMed: 23273890]
59. Cho CE, Norman M. Cesarean section and development of the immune system in the offspring. *Am J Obstet Gynecol*. 2013; 208:249–54. [PubMed: 22939691]
60. Mai V, Torrazza RM, Ukhanova M, Wang X, Sun Y, Li N, et al. Distortions in development of intestinal microbiota associated with late onset sepsis in preterm infants. *PloS One*. 2013; 8:e52876. [PubMed: 23341915]
61. Trasande L, Blustein J, Liu M, Corwin E, Cox LM, Blaser MJ. Infant antibiotic exposures and early-life body mass. *Int J Obes*. 2013; 37:16–23.
62. Berrington JE, Stewart CJ, Embleton ND, Cummings SP. Gut microbiota in preterm infants: assessment and relevance to health and disease. *Arch Dis Child Fetal Neonatal Ed*. 2013; 98:F286–90. [PubMed: 23009761]
63. Mueller NT, Whyatt R, Hoepner L, Oberfield S, Dominguez-Bello MG, Widen EM, et al. Prenatal exposure to antibiotics, cesarean section and risk of childhood obesity. *Int J Obes*. 2015; 39:665–70.
64. Murphy R, Stewart AW, Braithwaite I, Beasley R, Hancox RJ, Mitchell EA, et al. Antibiotic treatment during infancy and increased body mass index in boys: an international cross-sectional study. *Int J Obes*. 2014; 38:1115–9.
65. Azad MB, Bridgman SL, Becker AB, Kozyrskyj AL. Infant antibiotic exposure and the development of childhood overweight and central adiposity. *Int J Obes*. 2014; 38:1290–8.
66. Bailey LC, Forrest CB, Zhang P, Richards TM, Livshits A, DeRusso PA. Association of antibiotics in infancy with early childhood obesity. *JAMA Pediatr*. 2014; 168:1063–9. [PubMed: 25265089]
67. Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. *Lancet DiabetesEndocrinol*. 2015; 3:207–15.
68. Li M, Wang M, Donovan SM. Early development of the gut microbiome and immune-mediated childhood disorders. *Semin Reprod Med*. 2014; 32:74–86. [PubMed: 24390924]
69. Romero R, Miranda J, Kusanovic JP, Chaiworapongsa T, Chaemsathong P, Martinez A, et al. Clinical chorioamnionitis at term I: microbiology of the amniotic cavity using cultivation and molecular techniques. *J Perinat Med*. 2015; 43:19–36. [PubMed: 25720095]
70. Romero R, Chaemsathong P, Korzeniewski SJ, Tarca AL, Bhatti G, Xu Z, et al. Clinical chorioamnionitis at term II: the intra-amniotic inflammatory response. *J Perinat Med*. 2016; 44:5–22. [PubMed: 25938217]
71. DiGiulio DB, Romero R, Amogan HP, Kusanovic JP, Bik EM, Gotsch F, et al. Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. *PLoS One*. 2008; 3:e3056. [PubMed: 18725970]
72. DiGiulio DB, Romero R, Kusanovic JP, Gomez R, Kim CJ, Seok KS, et al. Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy

- outcome in women with preterm pre-labor rupture of membranes. *Am J Reprod Immunol.* 2010; 64:38–57. [PubMed: 20331587]
73. DiGiulio DB, Gervasi M, Romero R, Mazaki-Tovi S, Vaisbuch E, Kusanovic JP, et al. Microbial invasion of the amniotic cavity in pre-eclampsia as assessed by cultivation and sequence-based methods. *J Perinat Med.* 2010; 38:503–13. [PubMed: 20482470]
 74. DiGiulio DB, Gervasi MT, Romero R, Vaisbuch E, Mazaki-Tovi S, Kusanovic JP, et al. Microbial invasion of the amniotic cavity in pregnancies with small-for-gestational-age fetuses. *J Perinat Med.* 2010; 38:495–502. [PubMed: 20482466]
 75. Jun JK, Yoon BH, Romero R, Kim M, Moon JB, Ki SH, et al. Interleukin 6 determinations in cervical fluid have diagnostic and prognostic value in preterm premature rupture of membranes. *Am J Obstet Gynecol.* 2000; 183:868–73. [PubMed: 11035328]
 76. Yoon BH, Romero R, Moon JB, Shim SS, Kim M, Kim G, et al. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. *Am J Obstet Gynecol.* 2001; 185:1130–6. [PubMed: 11717646]
 77. Madan I, Romero R, Kusanovic JP, Mittal P, Chaiworapongsa T, Dong Z, et al. The frequency and clinical significance of intra-amniotic infection and/or inflammation in women with placenta previa and vaginal bleeding: an unexpected observation. *J Perinat Med.* 2010; 38:275–9. [PubMed: 20146660]
 78. Cruciani L, Romero R, Vaisbuch E, Kusanovic JP, Chaiworapongsa T, Mazaki-Tovi S, et al. Pentraxin 3 in amniotic fluid: a novel association with intra-amniotic infection and inflammation. *J Perinat Med.* 2010; 38:161–71. [PubMed: 19792835]
 79. Romero R, Chaiworapongsa T, Alpay Savasan Z, Xu Y, Hussein Y, Dong Z, et al. Damage-associated molecular patterns (DAMPs) in preterm labor with intact membranes and preterm PROM: a study of the alarmin HMGB1. *J Matern Fetal Neonatal Med.* 2011; 24:1444–55. [PubMed: 21958433]
 80. Romero R, Chaiworapongsa T, Savasan ZA, Hussein Y, Dong Z, Kusanovic JP, et al. Clinical chorioamnionitis is characterized by changes in the expression of the alarmin HMGB1 and one of its receptors, sRAGE. *J Matern Fetal Neonatal Med.* 2012; 25:558–67. [PubMed: 22578261]
 81. Gervasi MT, Romero R, Bracalente G, Erez O, Dong Z, Hassan SS, et al. Midtrimester amniotic fluid concentrations of interleukin-6 and interferon-gamma-inducible protein-10: evidence for heterogeneity of intra-amniotic inflammation and associations with spontaneous early (<32 weeks) and late (>32 weeks) preterm delivery. *J Perinat Med.* 2012; 40:329–43. [PubMed: 22752762]
 82. Kim SK, Romero R, Savasan ZA, Xu Y, Dong Z, Lee DC, et al. Endoglin in amniotic fluid as a risk factor for the subsequent development of bronchopulmonary dysplasia. *Am J Reprod Immunol.* 2013; 69:105–23. [PubMed: 23279628]
 83. Romero R, Miranda J, Chaiworapongsa T, Chaemsathong P, Gotsch F, Dong Z, et al. A novel molecular microbiologic technique for the rapid diagnosis of microbial invasion of the amniotic cavity and intra-amniotic infection in preterm labor with intact membranes. *Am J Reprod Immunol.* 2014; 71:330–58. [PubMed: 24417618]
 84. Romero R, Miranda J, Chaemsathong P, Chaiworapongsa T, Kusanovic JP, Dong Z, et al. Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes. *J Matern Fetal Neonatal Med.* 2015; 28:1394–409. [PubMed: 25190175]
 85. Romero R, Miranda J, Chaiworapongsa T, Chaemsathong P, Gotsch F, Dong Z, et al. Sterile intra-amniotic inflammation in asymptomatic patients with a sonographic short cervix: prevalence and clinical significance. *J Matern Fetal Neonatal Med.* 2014 Sep;24:1–17.
 86. Romero R, Miranda J, Chaiworapongsa T, Korzeniewski SJ, Chaemsathong P, Gotsch F, et al. Prevalence and clinical significance of sterile intra-amniotic inflammation in patients with preterm labor and intact membranes. *Am J Reprod Immunol.* 2014; 72:458–74. [PubMed: 25078709]
 87. Chaemsathong P, Romero R, Korzeniewski SJ, Dong Z, Yeo L, Hassan SS, et al. A point of care test for the determination of amniotic fluid interleukin-6 and the chemokine CXCL-10/IP-10. *J Matern Fetal Neonatal Med.* 2015; 28:1510–9. [PubMed: 25182862]
 88. Kacerovsky M, Musilova I, Andrys C, Hornychova H, Pliskova L, Kostal M, et al. Prelabor rupture of membranes between 34 and 37 weeks: the intraamniotic inflammatory response and neonatal outcomes. *Am J Obstet Gynecol.* 2014; 210:325 e1–e10. [PubMed: 24184182]

89. Combs CA, Gravett M, Garite TJ, Hickok DE, Lapidus J, Porreco R, et al. Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes. *Am J Obstet Gynecol.* 2014; 210:125 e1–e15. [PubMed: 24274987]
90. Cobo T, Kacerovsky M, Jacobsson B. Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes. *Am J Obstet Gynecol.* 2014; 211:708.
91. Chaemsaihong P, Romero R, Korzeniewski SJ, Dong Z, Martinez-Varea A, Yoon BH, et al. A rapid interleukin-6 bedside test for the identification of intra-amniotic inflammation in preterm labor with intact membranes. *J Matern Fetal Neonatal Med.* 2016; 29:349–59. [PubMed: 25758618]
92. Chaemsaihong P, Romero R, Korzeniewski SJ, Dong Z, Martinez-Varea A, Yoon BH, et al. A point of care test for interleukin-6 in amniotic fluid in preterm prelabor rupture of membranes: a step toward the early treatment of acute intra-amniotic inflammation/infection. *J Matern Fetal Neonatal Med.* 2016; 29:360–7. [PubMed: 25758620]
93. Redline RW, Heller D, Keating S, Kingdom J. Placental diagnostic criteria and clinical correlation--a workshop report. *Placenta.* 2005; 26:S114–7. [PubMed: 15837060]
94. Redline RW. Inflammatory responses in the placenta and umbilical cord. *Semin Fetal Neonatal Med.* 2006; 11:296–301. [PubMed: 16621749]
95. Chaiworapongsa T, Erez O, Kusanovic JP, Vaisbuch E, Mazaki-Tovi S, Gotsch F, et al. Amniotic fluid heat shock protein 70 concentration in histologic chorioamnionitis, term and preterm parturition. *J Matern Fetal Neonatal Med.* 2008; 21:449–61. [PubMed: 18570125]
96. Seong HS, Lee SE, Kang JH, Romero R, Yoon BH. The frequency of microbial invasion of the amniotic cavity and histologic chorioamnionitis in women at term with intact membranes in the presence or absence of labor. *Am J Obstet Gynecol.* 2008; 199:375 e1–5. [PubMed: 18928978]
97. Park CW, Moon KC, Park JS, Jun JK, Romero R, Yoon BH. The involvement of human amnion in histologic chorioamnionitis is an indicator that a fetal and an intra-amniotic inflammatory response is more likely and severe: clinical implications. *Placenta.* 2009; 30:56–61. [PubMed: 19046766]
98. Kacerovsky M, Pliskova L, Bolehovska R, Musilova I, Hornychova H, Tambor V, et al. The microbial load with genital mycoplasmas correlates with the degree of histologic chorioamnionitis in preterm PROM. *Am J Obstet Gynecol.* 2011; 205:213 e1–7. [PubMed: 21663889]
99. Mi Lee S, Romero R, Lee KA, Jin Yang H, Joon Oh K, Park CW, et al. The frequency and risk factors of funisitis and histologic chorioamnionitis in pregnant women at term who delivered after the spontaneous onset of labor. *J Matern Fetal Neonatal Med.* 2011; 24:37–42. [PubMed: 20698737]
100. Tsiartas P, Kacerovsky M, Musilova I, Hornychova H, Cobo T, Savman K, et al. The association between histological chorioamnionitis, funisitis and neonatal outcome in women with preterm prelabor rupture of membranes. *J Matern Fetal Neonatal Med.* 2013; 26:1332–6. [PubMed: 23489073]
101. Korzeniewski SJ, Romero R, Cortez J, Pappas A, Schwartz AG, Kim CJ, et al. A “multi-hit” model of neonatal white matter injury: cumulative contributions of chronic placental inflammation, acute fetal inflammation and postnatal inflammatory events. *J Perinat Med.* 2014; 42:731–43. [PubMed: 25205706]
102. Kim SM, Romero R, Park JW, Oh KJ, Jun JK, Yoon BH. The relationship between the intensity of intra-amniotic inflammation and the presence and severity of acute histologic chorioamnionitis in preterm gestation. *J Matern Fetal Neonatal Med.* 2015; 28:1500–9. [PubMed: 25184305]
103. Yoon BH, Romero R, Park JS, Kim M, Oh SY, Kim CJ, et al. The relationship among inflammatory lesions of the umbilical cord (funisitis), umbilical cord plasma interleukin 6 concentration, amniotic fluid infection, and neonatal sepsis. *Am J Obstet Gynecol.* 2000; 183:1124–9. [PubMed: 11084553]
104. Park JS, Romero R, Yoon BH, Moon JB, Oh SY, Han SY, et al. The relationship between amniotic fluid matrix metalloproteinase-8 and funisitis. *Am J Obstet Gynecol.* 2001; 185:1156–61. [PubMed: 11717650]
105. Pacora P, Chaiworapongsa T, Maymon E, Kim YM, Gomez R, Yoon BH, et al. Funisitis and chorionic vasculitis: the histological counterpart of the fetal inflammatory response syndrome. *J Matern Fetal Neonatal Med.* 2002; 11:18–25. [PubMed: 12380603]

106. Yoon BH, Romero R, Shim JY, Shim SS, Kim CJ, Jun JK. C-reactive protein in umbilical cord blood: a simple and widely available clinical method to assess the risk of amniotic fluid infection and funisitis. *J Matern Fetal Neonatal Med.* 2003; 14:85–90. [PubMed: 14629087]
107. Lee SE, Romero R, Kim CJ, Shim SS, Yoon BH. Funisitis in term pregnancy is associated with microbial invasion of the amniotic cavity and intra-amniotic inflammation. *J Matern Fetal Neonatal Med.* 2006; 19:693–7. [PubMed: 17127492]
108. Park CW, Lee SM, Park JS, Jun JK, Romero R, Yoon BH. The antenatal identification of funisitis with a rapid MMP-8 bedside test. *J Perinat Med.* 2008; 36:497–502. [PubMed: 19127606]
109. Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. The fetal inflammatory response syndrome. *Am J Obstet Gynecol.* 1998; 179:194–202. [PubMed: 9704787]
110. Chaiworapongsa T, Romero R, Kim JC, Kim YM, Blackwell SC, Yoon BH, et al. Evidence for fetal involvement in the pathologic process of clinical chorioamnionitis. *Am J Obstet Gynecol.* 2002; 186:1178–82. [PubMed: 12066094]
111. Gotsch F, Romero R, Kusanovic JP, Mazaki-Tovi S, Pineles BL, Erez O, et al. The fetal inflammatory response syndrome. *Clin Obstet Gynecol.* 2007; 50:652–83. [PubMed: 17762416]
112. Kim SK, Romero R, Chaiworapongsa T, Kusanovic JP, Mazaki-Tovi S, Mittal P, et al. Evidence of changes in the immunophenotype and metabolic characteristics (intracellular reactive oxygen radicals) of fetal, but not maternal, monocytes and granulocytes in the fetal inflammatory response syndrome. *J Perinatal Med.* 2009; 37:543–52.
113. Madsen-Bouterse SA, Romero R, Tarca AL, Kusanovic JP, Espinoza J, Kim CJ, et al. The transcriptome of the fetal inflammatory response syndrome. *Am J Obstet Gynecol.* 2010; 63:73–92.
114. Romero R, Savasan ZA, Chaiworapongsa T, Berry SM, Kusanovic JP, Hassan SS, et al. Hematologic profile of the fetus with systemic inflammatory response syndrome. *J Perinat Med.* 2011; 40:19–32. [PubMed: 21957997]
115. Chaiworapongsa T, Romero R, Berry SM, Hassan SS, Yoon BH, Edwin S, et al. The role of granulocyte colony-stimulating factor in the neutrophilia observed in the fetal inflammatory response syndrome. *J Perinat Med.* 2011; 39:653–66. [PubMed: 21801092]
116. Vaisbuch E, Romero R, Gomez R, Kusanovic JP, Mazaki-Tovi S, Chaiworapongsa T, et al. An elevated fetal interleukin-6 concentration can be observed in fetuses with anemia due to Rh alloimmunization: implications for the understanding of the fetal inflammatory response syndrome. *J Matern Fetal Neonatal Med.* 2011; 24:391–6. [PubMed: 20701435]
117. Romero R, Soto E, Berry SM, Hassan SS, Kusanovic JP, Yoon BH, et al. Blood pH and gases in fetuses in preterm labor with and without systemic inflammatory response syndrome. *J Matern Fetal Neonatal Med.* 2012; 25:1160–70. [PubMed: 21988103]
118. Savasan ZA, Chaiworapongsa T, Romero R, Hussein Y, Kusanovic JP, Xu Y, et al. Interleukin-19 in fetal systemic inflammation. *J Matern Fetal Neonatal Med.* 2012; 25:995–1005. [PubMed: 21767236]
119. Stampalija T, Romero R, Korzeniewski SJ, Chaemsaihong P, Miranda J, Yeo L, et al. Soluble ST2 in the fetal inflammatory response syndrome: *in vivo* evidence of activation of the anti-inflammatory limb of the immune response. *J Matern Fetal Neonatal Med.* 2013; 26:1384–93.
120. Acker DB, Johnson MP, Sachs BP, Friedman EA. The leukocyte count in labor. *Am J Obstet Gynecol.* 1985; 153:737–9. [PubMed: 4073137]
121. Curtin WM, Katzman PJ, Florescu H, Metlay LA. Accuracy of signs of clinical chorioamnionitis in the term parturient. *J Perinatol.* 2013; 33:422–8. [PubMed: 23154669]
122. Olding L. Value of placentitis as a sign of intrauterine infection in human subjects. *Acta Pathol Microbiol Scand A, Pathol.* 1970; 78:256–64.
123. Pankuch GA, Appelbaum PC, Lorenz RP, Botti JJ, Schachter J, Naeye RL. Placental microbiology and histology and the pathogenesis of chorioamnionitis. *Obstet Gynecol.* 1984; 64:802–6. [PubMed: 6390279]
124. Zhang JM, Kraus FT, Aquino TI. Chorioamnionitis: a comparative histologic, bacteriologic, and clinical study. *Int J Gynecol Pathol.* 1985; 4:1–10. [PubMed: 3880150]
125. Dong Y, St Clair PJ, Ramzy I, Kagan-Hallet KS, Gibbs RS. A microbiologic and clinical study of placental inflammation at term. *Obstet Gynecol.* 1987; 70:175–82. [PubMed: 3601279]

126. Hillier SL, Martius J, Krohn M, Kiviat N, Holmes KK, Eschenbach DA. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. *N Engl J Med*. 1988; 319:972–8. [PubMed: 3262199]
127. Hillier SL, Witkin SS, Krohn MA, Watts DH, Kiviat NB, Eschenbach DA. The relationship of amniotic fluid cytokines and preterm delivery, amniotic fluid infection, histologic chorioamnionitis, and chorioamnion infection. *Obstet Gynecol*. 1993; 81:941–8. [PubMed: 8497360]
128. Roberts DJ, Celi AC, Riley LE, Onderdonk AB, Boyd TK, Johnson LC, et al. Acute histologic chorioamnionitis at term: nearly always non-infectious. *PloS One*. 2012; 7:e31819. [PubMed: 22412842]
129. Torricelli M, Voltolini C, Conti N, Vellucci FL, Orlandini C, Bocchi C, et al. Histologic chorioamnionitis at term: implications for the progress of labor and neonatal wellbeing. *J Matern Fetal Neonatal Med*. 2013; 26:188–92. [PubMed: 22928534]
130. Romero R, Sirtori M, Oyarzun E, Avila C, Mazor M, Callahan R, et al. Infection and labor. V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes. *Am J Obstet Gynecol*. 1989; 161:817–24. [PubMed: 2675611]
131. Cobo T, Kacerovsky M, Holst RM, Hougaard DM, Skogstrand K, Wennerholm UB, et al. Intra-amniotic inflammation predicts microbial invasion of the amniotic cavity but not spontaneous preterm delivery in preterm prelabor membrane rupture. *Acta Obstet Gynecol Scand*. 2012; 91:930–5. [PubMed: 22524241]
132. Klaus MH, Kennell JH. Mothers separated from their newborn infants. *Pediatr Clin N Am*. 1970; 17:1015–37.
133. Kratochvil MS, Robertson CM, Kyle JM. Parents' view of parent-child relationship eight years after neonatal intensive care. *Social Work in Health Care*. 1991; 16:95–118. [PubMed: 1839088]
134. Slonim AD, Patel KM, Ruttimann UE, Pollack MM. The impact of prematurity: a perspective of pediatric intensive care units. *Crit Care Med*. 2000; 28:848–53. [PubMed: 10752841]
135. Placencia FX, McCullough LB. Biopsychosocial risks of parental care for high-risk neonates: implications for evidence-based parental counseling. *J Perinatol*. 2012; 32:381–6. [PubMed: 21904297]
136. Lee SM, Romero R, Park JS, Chaemsaitong P, Jun JK, Yoon BH. A transcervical amniotic fluid collector: a new medical device for the assessment of amniotic fluid in patients with ruptured membranes. *J Perinat Med*. 2015; 43:381–9. [PubMed: 25372723]
137. Gotsch F, Romero R, Chaiworapongsa T, Erez O, Vaisbuch E, Espinoza J, et al. Evidence of the involvement of caspase-1 under physiologic and pathologic cellular stress during human pregnancy: a link between the inflammasome and parturition. *J Matern Fetal Neonatal Med*. 2008; 21:605–16. [PubMed: 18828051]

Table 1

Characteristics of the study population

	Clinical chorioamnionitis at term without microbial-associated intra-amniotic inflammation (n=20)	Clinical chorioamnionitis at term with microbial-associated intra-amniotic inflammation (n=25)	P value
Maternal age (years)	21.5 (18.25-25.75)	19 (18-24)	0.26
Nulliparity	50% (10/20)	76% (19/25)	0.07
Body mass index (kg/m ²)	23.75 (21.68-26.53)	23.5 (21.65-24.55)	0.59
Maternal tachycardia (heart rate > 100 beats/min)	95% (19/20)	88% (22/25)	0.41
Fetal tachycardia (heart rate > 160 beats/min)	70% (14/20)	80% (20/25)	0.43
Leukocytosis (white blood cell count > 15,000 cells/mm ³)	70% (14/20)	76% (19/25)	0.65
Foul-smelling AF	5% (1/20)	8% (2/25)	0.69
Uterine tenderness	5% (1/20)	12% (3/25)	0.41
3 criteria	45% (9/20)	56% (14/25)	0.46
4 criteria	0% (0/20)	8% (2/25)	0.20
AF white blood cell count (cells/mm ³)	5 (0-37.75)	300 (39-900)	<0.001
AF glucose (mg/dL)	9 (9-11.5)	9 (7-9)	0.01
AF IL-6 (ng/mL)	2.53 (0.91-4.40)	14.12 (5.73-36.85)	<0.001
AF IL-6 ≥ 2.6 ng/mL	50% (10/20)	100% (25/25)	<0.001
Maternal blood IL-6 (ng/mL)	2.54 (0.91-4.40)	0.009 (0.005-0.046)	0.92
Umbilical cord blood IL-6 (pg/mL)	2.70 (2.09-4.95)	6.52 (2.53-23.23)	0.03
Gestational age at delivery (weeks)	39.25 (38.38-39.85)	41.1 (39.6-41.1)	0.002
Gestational age at amniocentesis (weeks)	39.25 (38.19-39.83)	40.6 (39.6-41.1)	0.002
Birthweight (gram)	3385 (3035-3755)	3570 (3375-3800)	0.18
Neonatal sepsis	10% (2/20)	16% (4/25)	0.56
Fetal inflammatory response syndrome (FIRS)	5% (1/20)	36% (9/25)	0.03
Acute inflammatory lesions of the placenta ^a	25% (5/20)	70.8% (17/24) ^b	0.02

Data presented as median (interquartile) or % (n); AF: amniotic fluid; IL: interleukin.

^a Acute inflammatory lesions of the placenta: acute histologic chorioamnionitis and/or acute funisitis.^b A placental pathology report was not available for one patient.

Table 2

The diagnostic performance of clinical criteria for the identification of microbial associated intra-amniotic inflammation (intra-amniotic infection) in patients with clinical chorioamnionitis at term

Clinical signs	Sensitivity (%)		Specificity (%)		Positive Likelihood Ratio (95% CI)	Negative Likelihood Ratio (95% CI)	Accuracy (%)
	% (n)	95% CI	% (n)	95% CI			
Maternal tachycardia (heart rate > 100 beats/min)	88.0 (22/25)	(68.75-97.31)	5.0 (1/20)	(0.83-24.95)	0.93 (0.78-1.10)	2.40 (0.27-21.35)	51.1 (23/45)
Fetal tachycardia (heart rate > 160 beats/min)	80.0 (20/25)	(59.29-93.09)	30 (6/20)	(11.97-54.27)	1.14 (0.81-1.62)	0.67 (0.24-1.87)	57.8 (26/45)
White blood cell count > 15,000	76 (19/25)	(54.87-90.58)	30 (6/20)	(11.97-54.27)	1.09 (0.76-1.56)	0.80 (0.30-2.10)	55.6 (25/45)
Foul-smelling AF	8.00 (2/25)	(1.22-26.07)	95 (19/20)	(75.05-99.17)	1.6 (0.16-16.40)	0.97 (0.83-1.13)	46.7 (21/45)
Uterine tenderness	12.0 (3/25)	(2.69-31.25)	95 (19/20)	(75.05-99.17)	2.40 (0.27-21.35)	0.93 (0.78-1.10)	48.9 (22/45)
3 criteria	56.00 (14/25)	(34.94-75.57)	55 (11/20)	(31.55-76.90)	1.24 (0.69-2.26)	0.80 (0.44-1.45)	55.6 (25/45)
4 criteria	8.00 (2/25)	(1.22-26.07)	100 (20/20)	(83.01-100)	0.92 (0.82-1.03)	–	48.9 (22/45)

CI: confidence interval; AF: amniotic fluid.

Microbial-associated intra-amniotic inflammation: presence of microorganisms in AF and intra-amniotic inflammation [amniotic fluid interleukin-6 2.6 ng/mL; n=25/45 (55.56%)].

Table 3

The diagnostic performance of clinical signs for the identification of intra-amniotic inflammation in patients with clinical chorioamnionitis at term

Clinical signs	Sensitivity (%)		Specificity (%)		Positive Likelihood Ratio (95% CI)	Negative Likelihood Ratio (95% CI)	Accuracy (%)
	% (n)	95% CI	% (n)	95% CI			
Maternal tachycardia (heart rate > 100 beats/min)	88.57 (31/35)	(73.24-96.73)	0 (0/10)	(0-31.03)	0.89 (0.79-1.00)	–	68.8 (31/45)
Fetal tachycardia (heart rate > 160 beats/min)	77.14 (27/35)	(59.86-89.55)	30 (3/10)	(7.03-65.16)	1.10 (0.71-1.72)	0.76 (0.25-2.35)	66.67 (30/45)
White blood cell count > 15,000	74.30 (26/35)	(56.74-87.48)	30 (3/10)	(7.03-65.16)	1.06 (0.68-1.66)	0.86 (0.28-2.58)	64.4 (29/45)
Foul-smelling AF	5.71 (2/35)	(0.87-19.19)	90.0 (9/10)	(55.46-98.34)	0.57 (0.06-5.67)	1.05 (0.84-1.31)	24.44 (11/45)
Uterine tenderness	8.57 (3/35)	(1.90-23.08)	90.0 (9/10)	(55.46-98.34)	0.86 (0.10-7.37)	1.02 (0.81-1.28)	26.67 (12/45)
3 criteria	48.57 (17/35)	(31.39-66.00)	40.0 (4/10)	(12.40-73.63)	0.81 (0.44-1.49)	1.29 (0.56-2.93)	46.67 (21/45)
4 criteria	5.71 (2/35)	(0.87-19.19)	100 (10/10)	(68.97-100)	–	0.94 (0.87-1.02)	26.67 (12/45)

CI: confidence interval; AF: amniotic fluid.

Intra-amniotic inflammation (includes both microbial-associated intra-amniotic inflammation and intra-amniotic inflammation without demonstrable microorganisms); amniotic fluid interleukin-6 ng/mL; n=35/45 (77.78%).